Articles tagged with Tuberculosis
Scientists have identified MMP-1 as a key enzyme responsible for destroying lung tissue in tuberculosis, leading to the development of drugs that can prevent this damage. The findings suggest that existing MMP inhibitor drugs may be effective in reducing deaths from TB.
A team of researchers has identified a key role for the protein fibulin-5 in preventing pelvic organ prolapse (POP) in mice. Fibulin-5 prevents POP by facilitating the assembly of normal elastic fibers and inhibiting the activity of MMP9, a protein that degrades these fibers. Increased levels of MMP-9 were found in vaginal tissue sampl...
A study finds that the UK's current tuberculosis screening policy for immigrants is missing 70% of imported latent infections. Implementing a broader screening program could identify 92% of infected immigrants and reduce future cases of active tuberculosis while remaining cost-effective.
A new study published in The Lancet Infectious Diseases found that UK immigration screening procedures fail to detect over 70% of latent tuberculosis (TB) cases, with better selection of immigrants to screen increasing detection rates to over 90%. Treating people at an early stage can prevent them from developing active TB and becoming...
A new TB test has been shown to detect tuberculosis and multi-drug resistant TB with high sensitivity and specificity in resource-poor settings. The test can rapidly diagnose those infected, including those with MDR-TB, and reduce delays in diagnosis and treatment.
Researchers found a link between the fur trade routes and modern-day patterns of tuberculosis. The particular TB strain was introduced to remote Aboriginal populations in Canada by French Canadian fur traders during this period.
A new study published in JAMA found that a 4-drug fixed-dose regimen is noninferior to separate drug treatment for tuberculosis, with 93.9% of patients in the FDC group achieving favorable outcomes. This regimen simplifies treatment and reduces the risk of drug resistance.
A study by Stanford scientists found a specific TB strain was unintentionally spread among indigenous peoples of western Canada, leading to epidemics decades later. Poor living conditions and malnutrition on reservations contributed to the outbreak.
Researchers have developed an innovative diagnostic algorithm using a protein named HBHA in combination with IGRA, allowing for rapid identification of those infected but not yet showing symptoms. The new test has the potential to improve TB diagnosis and control strategies worldwide.
The BCG World Atlas is a first-of-its-kind resource providing detailed information on current and past TB vaccination policies and practices across 180+ countries. Clinicians can use this atlas to inform diagnosis and treatment decisions, particularly for foreign-born adults with unclear vaccination histories.
The BCG World Atlas offers detailed information on current and past vaccination policies across over 180 countries. This database aims to improve the care of patients with tuberculosis (TB) by providing useful resources for clinicians, policymakers, and researchers.
Researchers identified a protein called EspC that triggers a stronger immune response in people infected with TB bacteria, making it a promising new vaccine candidate. The protein could also be used to improve diagnosis of TB and underpin next-generation diagnostic blood tests.
Increasing rates of drug-resistant TB pose a significant threat to global progress in controlling the disease. The growing burden of TB is also linked to other risk factors like smoking and diabetes, which increase the risk of contracting the disease by two- and three-fold, respectively.
A study in Uganda found that the standard TB retreatment regimen has low treatment response rates, particularly among HIV-infected and multi-drug resistant TB patients. Poor adherence, HIV infection, age, and duration of symptoms were associated with unsuccessful outcomes.
A study published in PLoS Medicine found that re-treatment TB regimens are failing in low- and middle-income settings, with up to one-fourth of patients experiencing relapse or death. Researchers emphasize the need for tailored treatments depending on HIV status and improved access to antiretroviral therapies.
Researchers found that multi-drug tolerant organisms can form within days of infection in zebrafish and grow inside host macrophages, helping to promote the continuation of TB. Inexpensive drugs like verapamil may block tolerance mechanisms, potentially shortening treatment duration.
Researchers used whole genome sequencing to analyze TB bacterial samples from 41 patients. The study found that the outbreak was caused by bursts of transmission, rather than chains of infection.
Researchers at VIB and Ghent University have developed a new tuberculosis vaccine that affords better protection against the disease by triggering an immune reaction in the body. The new vaccine works differently from existing vaccines and acquires its extra protective value by emitting signals that provoke inflammation.
A study by St. Michael's Hospital found that one in five homeless people with tuberculosis die within a year of diagnosis, emphasizing the need for enhanced prevention and treatment strategies.
Scientists at EMBL identified a multi-tasking protein PriA from Mycobacterium tuberculosis that catalyzes reactions on two different molecules. This finding presents new opportunities for developing organism-specific drugs, targeting the pathogen but leaving other beneficial microorganisms untouched.
A recent outbreak of tuberculosis in Nunavut, with a population infection rate 62 times the Canadian average, underscores the need for rebuilding trust in public health. The territory's historical legacy of mistreating patients and lack of consistent screening measures have hindered control efforts.
A new study reveals that standardized medication dosages for children with tuberculosis are too low and may not be effective due to individual variations in response. The researchers used computer simulations to determine how a child's body handles the medication, highlighting the need for personalized treatment plans.
Researchers combined two proteins and a stress response protein to create a new TB vaccine strategy that provided stronger, more long-lasting protection than the current BCG vaccine. The study found that this multistage vaccine controlled reactivation of latent infection and reduced Mtb levels in the lungs more effectively.
A simple, standardized TB screening rule has been developed for resource-constrained settings to identify people living with HIV who need further investigation for TB disease. The absence of common symptoms such as cough, fever, and night sweats can be used to identify individuals with a low probability of having TB disease.
Researchers studied TB detection methods in western Kenya and found that passive case finding is inadequate due to the high prevalence of HIV. Intensive methods like sputum culture are needed to diagnose TB earlier and more accurately, especially among men and those with prior TB treatment.
A new study published in CMAJ found that people over 65 undergoing latent tuberculosis infection therapy are at a higher risk of severe adverse reactions requiring hospitalization. The study provides age-stratified estimates of the risk of these events, accounting for comorbidities and similar health events in the general population.
New research shows vitamin D can speed up antibiotic treatment of tuberculosis (TB), clearing bacteria from the lungs in just 5 weeks for certain patients. Vitamin D deficiency is a common problem among TB patients, and those with a specific genetic type of vitamin D receptor responded better to supplementation.
A new study found that supplementing antibiotics with high-dose vitamin D can significantly reduce the time needed for TB bacteria to clear from sputum culture by almost a week in patients with specific genetic profiles. The treatment improved response in those with the tt genotype of the TaqI vitamin D receptor polymorphism.
A China Medical University study shows a 10.9-fold increased risk of lung cancer among people with tuberculosis compared to those without the disease. The study followed over 1 million patients and found a mortality rate of 51.1 per 10,000 person-years in the tuberculosis group, nearly six times that of non-tuberculosis patients.
The Lancet's Editorial in 1911 highlighted issues such as tuberculosis, occupational health, and homoeopathy, which remain relevant today. The journal has made significant advances in medicine since then, including modernizing medical education.
A systematic review found that prison TB spread significantly increases the incidence of TB in the general population. The average incidence of TB in prisons was 23 times higher than in the general population.
The UK is experiencing a resurgence of tuberculosis, with London accounting for over 40% of all TB cases. The disease is concentrated in high-risk groups, including migrants, homeless people, and prisoners. Experts call for urgent recommendations to be implemented to control the spread.
Researchers found that Mycobacterium chelonae, a common environmental bacterium, can decrease the effectiveness of the bacille Calmette-Guerin (BCG) vaccine. The study suggests that immune cells exposed to this bacterium may dampen vaccine efficacy. This discovery could lead to new, more effective vaccines against tuberculosis.
Two iron compounds have been synthesized to inhibit the growth of Mycobacterium tuberculosis in vitro. The compounds showed low toxicity in mammalian cells, making them promising candidates for treating tuberculosis and serving as hospital disinfectants.
A combination of increased domestic funding and foreign loans led to a dramatic increase in tuberculosis case finding in China. The study highlights the importance of evaluating the links between financing for health and TB control.
Researchers have developed an inhalable dry powder antibiotic targeting TB, potentially reducing treatment time from 6-12 months to under a year. The novel treatment aims to distribute antibiotics directly to lung lesions, increasing targeted doses and minimizing side effects.
Scientists identified a key enzyme in Mycobacterium tuberculosis that can be targeted for new TB treatments. Three compounds were found to inhibit the enzyme effectively, killing bacterial cells.
The microscopic observation drug susceptibility (MODS) test has been endorsed by WHO for use in resource-poor settings. The test delivers positive culture and drug resistance results within two weeks for less than $3 per test, improving TB diagnosis and treatment.
The Aeras Global TB Vaccine Foundation has received an additional €11.7 million grant from the Netherlands Ministry of Foreign Affairs to develop new vaccines against tuberculosis.
Weill Cornell Medical College has received $200,000 in new funding from the Gates Foundation for tuberculosis research. The grants will support projects led by Dr. Carl Nathan and Dr. Kyu Rhee, aiming to understand the genetic mechanism of TB emergence from latency and develop new therapies.
Researchers linked hundreds of approved drugs to M. tuberculosis proteins, identifying new anti-tuberculosis targets and repurposing potential. The study provides a promising computational strategy for novel drug discovery.
Researchers found that people with periodontal disease are at high risk for cardiovascular disease and that invasive dental procedures may raise this risk. However, studies have not consistently shown a link between these procedures and cardiovascular events. Meanwhile, peer support programs improved diabetes management in patients, su...
Scientists discovered a key difference in how TB bacteria and human cells deliver unwanted proteins to their respective recycling factories. This critical difference may help design drugs to disable the bacterial system while leaving normal human protein recycling centers intact.
A new tool has been developed to tackle tuberculosis by integrating genomic and metabolic data, enabling cell-scale simulations and biological strain design. The probabilistic regulation of metabolism (PROM) algorithm accurately predicts knockout phenotypes 95% of the time, paving the way for targeted research during dormancy.
The Aeras Global TB Vaccine Foundation has received a $362,102 grant from the US FDA to develop new biological and immunological biomarkers for TB vaccine development. The project aims to evaluate four mycobacterial growth inhibition assays and identify T-cell immune responses associated with protective vaccines.
A mobile van approach to hunt down active cases of tuberculosis significantly outperformed door-to-door visits, detecting 255 smear-positive patients vs. 137 through door-to-door visits. This intervention led to a 43% decline in undiagnosed culture-positive TB in the community.
Kathleen Alexander has discovered a novel tuberculosis species, M. mungi, in banded mongooses, which behaves differently from other TB infections, killing infected animals within two to three months. The pathogen's source and host range are areas of ongoing research.
A computer model shows that the US is susceptible to MDR-TB epidemics when TB prevalence falls and case detection improves, even with high treatment compliance. This is attributed to the increased risk of drug-resistant TB spreading in populations with low drug-susceptible TB rates.
Dr. Jerrold J. Ellner leads an international research team to identify biological markers for tuberculosis (TB) and develop novel treatments and vaccines. The five-year grant aims to prevent TB, which kills nearly two million people annually.
Researchers at NPL and Orla Protein Technologies are developing improved TB detection methods to enhance sensitivity, specificity, cost and speed. The project aims to create systems that advance current methods, helping improve healthcare in resource-limiting settings.
A new TB vaccine candidate called AERAS-422 is undergoing clinical trials to evaluate its safety and immunogenicity. The vaccine aims to interrupt TB at all stages of infection, including initial infection, latency, and reactivation.
The Phase II study will establish the optimal dosing regimen and then be tested in Kenya, Mozambique, South Africa, and Uganda. The TB vaccine candidate has been shown to have an acceptable safety profile in early-stage clinical trials.
Recent research suggests that some TB vaccines under study may not be effective in older people, as the molecule responsible for immune response activation remains relatively inactive. The study's findings highlight the need for a new approach to vaccine development to ensure protection against tuberculosis for the elderly.
A computer model found a network of genes that can trigger TB's dormant state, switching it from fast-growing to slow-growing. The study reveals potential for a persistence switch that could explain why TB is so widespread and deadly.
Researchers discovered that mycobacteria block phagosome maturation with acyltrehalose-containing glycolipids, surviving and thriving inside host macrophages. This study sheds light on the mechanism of intracellular parasitism and identifies potential new drug targets for TB treatment.
A team from Case Western Reserve University has identified a novel dual recognition mechanism in Mycobacterium tuberculosis that may contribute to immune evasion. The discovery could aid in the design of new vaccines and antibiotics to combat the disease.
A new molecular test has been shown to diagnose tuberculosis (TB) and detect drug-resistant bacteria with high sensitivity and specificity. The Xpert MTB/RIF TB test successfully identified 98% of confirmed TB cases and patients with rifampin-resistant bacteria in under two hours.
Scientists at Nationwide Children's Hospital have discovered a distinct blood transcriptional signature associated with active TB, which may help identify patients at risk of developing the disease. The study found that this signature was present in 10-20% of latent TB patients and correlated with disease extent in active TB patients.
The Open Source Drug Discovery (OSDD) Consortium is a worldwide scientific community working together to discover and develop new drugs. Key findings include the development of a comprehensive map of Mycobacterium tuberculosis genome, paving the way for a potential new drug for tuberculosis.
Researchers will study immune cells to identify biomarkers associated with TB infection and disease reactivation. The joint laboratory aims to develop early diagnosis and effective treatment for the highly contagious disease, affecting millions worldwide.